{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:07:05Z","timestamp":1732036025085},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"None","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12664-016-0632-5","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:53:47Z","timestamp":1460768027000},"page":"75-82","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiviral therapy with nucleotide\/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials"],"prefix":"10.1007","volume":"35","author":[{"given":"Renesh H.","family":"Bedre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utkarsh","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Prakash","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritish Kumar","family":"Varadwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"632_CR1","unstructured":"Hepatitis B: fact sheet N\u00b0204. Geneva. World Health Organization. Retrieved 2013-09-19."},{"key":"632_CR2","volume":"8","author":"F Xie","year":"2013","unstructured":"Xie F, Yan L, Lu J, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8, e54773.","journal-title":"PLoS One"},{"key":"632_CR3","first-page":"17","volume":"2","author":"H Ke-Qin","year":"2005","unstructured":"Ke-Qin H. A practical approach to management of chronic hepatitis B. Int J Med Sci. 2005;2:17\u201323.","journal-title":"Int J Med Sci"},{"key":"632_CR4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1445-5994.2006.01027.x","volume":"36","author":"GC Farrell","year":"2006","unstructured":"Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Int Med J. 2006;36:100\u201313.","journal-title":"Int Med J"},{"key":"632_CR5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/phar.1188","volume":"33","author":"A Wiens","year":"2013","unstructured":"Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144\u201351.","journal-title":"Pharmacotherapy"},{"key":"632_CR6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13:934\u201345.","journal-title":"Value Health"},{"key":"632_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14712598.2011.546340","volume":"11","author":"M Vigan\u00f2","year":"2011","unstructured":"Vigan\u00f2 M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther. 2011;11:285\u2013300.","journal-title":"Expert Opin Biol Ther"},{"key":"632_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/liv.12078","volume":"33","author":"G Dusheiko","year":"2011","unstructured":"Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2011;33:137\u201350.","journal-title":"Liver Int"},{"key":"632_CR9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhep.2001.26815","volume":"34","author":"RA Man de","year":"2001","unstructured":"de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001;34:578-82..","journal-title":"Hepatology"},{"key":"632_CR10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","volume":"44","author":"M Zeng","year":"2006","unstructured":"Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovirdipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44:108\u201316.","journal-title":"Hepatology"},{"key":"632_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135965350701200308","volume":"12","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12:345\u201353.","journal-title":"Antivir Ther"},{"key":"632_CR12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","volume":"346","author":"MM Jonas","year":"2002","unstructured":"Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002;346:1706\u201313.","journal-title":"N Engl J Med"},{"key":"632_CR13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"48","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Adefovirdipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;48:808\u201316.","journal-title":"N Engl J Med"},{"key":"632_CR14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Nicolaos C, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800\u20137.","journal-title":"N Engl J Med"},{"key":"632_CR15","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"SJ Hadziyannis","year":"2005","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673\u201381.","journal-title":"N Engl J Med"},{"key":"632_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","volume":"166","author":"SG Lim","year":"2006","unstructured":"Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49\u201356.","journal-title":"Arch Intern Med"},{"key":"632_CR17","doi-asserted-by":"crossref","unstructured":"Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61\u20138.","DOI":"10.1056\/NEJM199807093390201"},{"key":"632_CR18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","volume":"29","author":"NC Tassopoulos","year":"1999","unstructured":"Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889\u201396.","journal-title":"Hepatology"},{"key":"632_CR19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046\u201355.","journal-title":"J Clin Epidemiol"},{"key":"632_CR20","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J. 2004;4:127\u201341.","DOI":"10.1177\/1536867X0400400204"},{"key":"632_CR21","doi-asserted-by":"crossref","unstructured":"Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? CHIP Documents 2006. Paper 19.","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"632_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hep.510250144","volume":"25","author":"CL Lai","year":"1997","unstructured":"Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25:241\u20134.","journal-title":"Hepatology"},{"key":"632_CR23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"632_CR24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","volume":"45","author":"M Kumar","year":"2007","unstructured":"Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97\u2013101.","journal-title":"Hepatology"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-016-0632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12664-016-0632-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-016-0632-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T23:19:42Z","timestamp":1655507982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12664-016-0632-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1007\/s12664-016-0632-5","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}